Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.77
Nov 19 • 3:59 PM ET Dollar change-0.12 Percentage change(-6.35%)
Aftermarket Close
1.89
Aftermarket • 6:17 PM ET Dollar change+0.12 Percentage change(6.78%)
Index
-
Market Cap
59.03M
Enterprise Value
-37.19M
Income
91.84M
Sales
69.99M
Book/sh
4.78
Cash/sh
4.56
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
78
IPO
Nov 17, 2011
P/E
0.77
Forward P/E
2.58
PEG
-
P/S
0.84
P/B
0.37
P/C
0.39
P/FCF
0.49
EV/EBITDA
-
EV/Sales
-0.53
Quick Ratio
2.82
Current Ratio
2.93
Debt/Eq
0.24
LT Debt/Eq
0.18
Option/Short
Yes / Yes
EPS (ttm)
2.31
EPS next Y
0.69
EPS next Q
-0.20
EPS this Y
3821.43%
EPS next Y
-73.70%
EPS next 5Y
-
EPS past 3/5Y
83.35% 62.98%
Sales past 3/5Y
-5.83% 6.77%
EPS Y/Y TTM
1602.82%
Sales Y/Y TTM
12.34%
EPS Q/Q
-309.64%
Sales Q/Q
8.67%
Insider Own
30.90%
Insider Trans
1.82%
Inst Own
24.78%
Inst Trans
0.78%
ROA
43.38%
ROE
92.77%
ROIC
52.99%
Gross Margin
59.72%
Oper. Margin
-42.47%
Profit Margin
131.21%
SMA20
-7.11%
SMA50
-14.40%
SMA200
-34.09%
Trades
Shs Outstand
33.49M
Shs Float
23.04M
52W High
4.53 -60.93%
52W Low
1.64 7.93%
Volatility
9.94% 6.27%
ATR (14)
0.13
RSI (14)
40.84
Beta
1.24
Rel Volume
0.70
Avg Volume
279.26K
Volume
196,340
Perf Week
-11.06%
Perf Month
-8.76%
Perf Quarter
-38.33%
Perf Half Y
-36.33%
Perf YTD
-51.64%
Perf Year
-31.92%
Perf 3Y
-15.31%
Perf 5Y
-96.18%
Perf 10Y
-95.44%
Prev Close
1.89
Price
1.77
Change %
-6.35%
Consensus
Strong Buy
Avg. Price Target
$11.00
Implied Upside
+521.5%
Analysts8incl. previous ratings
Rating Distribution8 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 15, 2024Resumed
RROTH MKM
Buy$10+465.0%
Aug 04, 2022Initiated
LLadenburg Thalmann
Buy$6+239.0%
Oct 02, 2020Initiated
TThe Benchmark Company
Buy$9+408.5%
Dec 18, 2019Initiated
BB. Riley FBR
Buy$9+408.5%
Feb 28, 2018Initiated
BB. Riley FBR, Inc.
Buy$10+465.0%
Jul 11, 2017Initiated
RRodman & Renshaw
Buy$11+521.5%
Mar 22, 2017Initiated
JJMP Securities
Mkt Outperform
Oct 03, 2016Initiated
RROTH Capital
Buy$9+408.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMANNov 17 '26Buy1.8064,491115,9104,651,332Nov 19 05:59 PM
ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMANNov 18 '26Buy1.9054,776104,2334,706,108Nov 19 05:59 PM
ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMANNov 19 '26Buy1.8617,45632,4404,723,564Nov 19 05:59 PM
Jin DavidChief Financial OfficerNov 18 '26Buy1.9125,00047,7981,692,761Nov 19 05:54 PM
Jin DavidChief Financial OfficerNov 17 '26Buy1.7215,00025,7961,667,761Nov 19 05:54 PM
Jin DavidChief Financial OfficerNov 19 '26Buy1.877,60514,2211,700,366Nov 19 05:54 PM
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Executive ChairmanDr. Lindsay Allan Rosenwald M.D.
CFO & Head of Corporate DevelopmentMr. David Jin
Chief Strategy OfficerDr. Xiaoqin Lu M.D.
J.D.Mr. Michael S. Weiss Esq.